论文部分内容阅读
对于高新技术企业来说,不仅要有创新的技术和产品,与时俱进地调整技术创新的决策和产品定位也是十分关键的。1998年微创公司成立前,一种治疗冠心病的手术全国一年只作3000例,几年后,用微创的药物支架每七八分钟就能救一命,这是当年采访微创董事长常兆华时提供给记者的数据。而如今这个数据已经下降到平均每30秒左右。凭借小小的支架,微创撬动了医疗器械的大市场。今年8月,微创启动集团化运作模式,并于2012年9月获准更名为上海微创医疗器械(集团)有限公司。目前下辖上海微创骨科医疗科技有限公司、上
For high-tech enterprises, it is also crucial to not only have innovative technologies and products, but also to adjust the technological innovation decision-making and product positioning with the times. Before the establishment of minimally invasive company in 1998, a kind of operation to treat coronary heart disease was made in China for only 3000 cases a year. After a few years, a mini-invasive drug stent could save every seven or eight minutes. This was the interview with Minimally Invasive Directors Changzhao Hua when the data provided to reporters. And now this figure has dropped to an average of about 30 seconds. With a small stent, minimally invasive leveraging the medical equipment market. In August this year, Minimally Invasive started the group operation mode, and in September 2012 was approved to change its name to Shanghai Minimally Invasive Medical Devices (Group) Co., Ltd. Currently under the jurisdiction of Shanghai minimally invasive orthopedic medical technology Co., Ltd., on